Download ESMO Guideline 2015: European Society for Medical Oncology

 ESMO Guideline 2015: European Society for Medical Oncology
recommends EndoPredict® for breast cancer patients.
Cologne, 15 September 2015 – In its recently published ”Clinical Practice Guidelines”, the
European Society for Medical Oncology (ESMO) advocates the use of the EndoPredict gene
expression test for primary diagnosis in breast cancer patients. The test should be used in
women for whom no clear indication for or against adjuvant chemotherapy can be established.
In these women, the test can predict the individual risk of recurrence and the benefit of
chemotherapy, confirms the scientific body.
EndoPredict is a second generation gene expression test covering not only disease-relevant
tumour genes but also classical clinical prognostic factors (tumour size and nodal status).
Based on the test result, the patients can be assigned to a high or low risk group. High risk
patients are recommended to undergo chemotherapy because of the increased therapeutic
benefit. Low risk patients can do without the stressful procedure.
About 60 % of the tested patients can be assigned to the low risk group. Without the test, the
majority of these women would receive chemotherapy. The additional information provided by
the EndoPredict test helps to avoid overtreatment and serious side effects.
The test can be performed decentrally in the local pathology department. It is already used in
Europe and worldwide on a regular basis to determine breast cancer patients’ prognoses.
EndoPredict is produced by Sividon Diagnostics, a company based in Germany (Cologne) and
specialised in the development of molecular diagnostic tests. ”Women in an increasing number
of countries can benefit from EndoPredict since the introduction of the test in 2011”, says PD
Dr. Ralf Kronenwett, Head of Research and Development at Sividon. ”The test has now become
a generally accepted part of treatment guidelines, not only in Germany but also
internationally.”
In addition to the new ESMO Guidelines, EndoPredict is already recommended by the therapy
guidelines of the Working Group for Gynaecological Oncology (AGO) and the St. Gallen
Consensus Conference.
The ”Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up” have been published at the following link:
http://annonc.oxfordjournals.org/content/26/suppl_5/v8.full.pdf+html
Sividon Diagnostics GmbH was founded in July 2010 as a management buyout from Siemens Healthcare Diagnostics
Products in Cologne, Germany. The company aims to sustainably increase the quality of therapy-accompanying
diagnostics in oncology. EndoPredict®, the first diagnostic test from Sividon, has been available since 2011.
Further information is available at www.sividon.com or www.endopredict.com.
Press contact:
Sividon Diagnostics GmbH
Esther Linnenberg
Nattermannallee 1 | S19
50829 Köln
Phone: 0221/ 669 561 70
Fax: 0221/ 669 561 99
Email: [email protected]